Fenbendazole & Cancer Research
The veterinary antiparasitic that captured oncology's attention — mechanisms, studies, and the Joe Tippens protocol.
📋 On this page
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Medical Disclaimer: Fenbendazole is NOT FDA-approved for human use. This page presents pre-clinical research and community anecdotes for educational purposes only. Nothing here constitutes medical advice. Do not use fenbendazole as a replacement for conventional cancer treatment. Consult your oncologist before considering any off-label compound.
How It Works
Three simultaneous anticancer mechanisms identified in Dogra et al. (2018) and subsequent research
Microtubule Disruption
Fenbendazole binds tubulin and disrupts microtubule polymerization — the same mechanism as taxane chemotherapy agents. This halts cell division (mitotic arrest) and triggers apoptotic cell death, particularly in rapidly dividing cancer cells.
Glucose Inhibition
Cancer cells are heavily dependent on glucose via the Warburg effect. Fenbendazole downregulates GLUT4 glucose transporter expression and hexokinase activity, starving cancer cells of their preferred energy source while normal cells adapt more readily.
p53 Reactivation
The p53 tumor suppressor gene is mutated or silenced in ~50% of human cancers. Fenbendazole has been shown to reactivate p53-mediated apoptosis pathways, potentially restoring a key natural defense against uncontrolled cell growth.
Multi-Pathway Synergy
Unlike single-target agents, fenbendazole acts simultaneously on cytoskeletal integrity, metabolic pathways, and tumor suppression. This multi-pathway approach may reduce the likelihood of resistance development compared to single-mechanism drugs.
Research Evidence Strength
Evidence levels across cancer types — in vitro and animal model data only; no completed human trials
Community Dosing Protocols
These are community-derived protocols — NOT clinical guidelines. Consult a physician before use.
Pairing Fenbendazole with Ivermectin
A combination approach popularized by Dr. William Makis, a Canadian radiologist/oncologist who documents repurposed-drug cancer cases. The tiers below are reported, anecdotal protocols — not clinical guidelines — and pair fenbendazole with ivermectin rather than using either alone.
Where the Joe Tippens protocol uses fenbendazole on its own, the Makis approach adds ivermectin — another off-patent antiparasitic with overlapping anticancer mechanisms (it shares fenbendazole's microtubule/glucose effects and adds Wnt-pathway and mitochondrial activity). Makis scales both drugs together across three intensity tiers based on disease stage, dosing ivermectin by body weight (mg/kg) and fenbendazole by the familiar 222–1000 mg range. Ivermectin is typically cycled 3 weeks on / 1 week off and, like fenbendazole, taken with a fatty meal for absorption.
Drug selection by cancer type: Makis pairs ivermectin with whichever benzimidazole fits the cancer — fenbendazole for prostate, pancreatic, breast, lung, lymphoma, melanoma and sarcoma; mebendazole (better blood-brain-barrier penetration) for brain, ovarian and colorectal; both benzimidazoles plus ivermectin for advanced/refractory disease. For the full Big-3 breakdown, supplement stack, monitoring schedule and published-study evidence, see the dedicated Dr. Makis protocol guide.
These protocols come from clinical case documentation and patient reports, not controlled trials. Educational purposes only — not medical advice. Discuss any repurposed-drug protocol with your oncologist before starting.
Safety Profile
Risk indicators based on available pre-clinical data and community reports
🩺 Organ Risk Assessment
✅ Monitoring Recommendations
Key Research Citations
Peer-reviewed studies and clinical reports — pre-clinical unless noted
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
The landmark study. Demonstrates fenbendazole induces mitotic arrest and apoptosis in NSCLC cells via tubulin disruption, GLUT4 downregulation, and p53 pathway reactivation. Oral administration reduced tumor size in mouse xenograft models at doses tolerated without significant toxicity.
→ View on PubMed / DOIFenbendazole and Vitamin E Succinate Combination — Tumor Inhibition Study
The same research group found that combining fenbendazole with Vitamin E succinate (not tocopherol acetate) produced synergistic tumor suppression. This finding forms the rationale for including Vitamin E succinate specifically in community protocols.
→ Full PaperAnticancer Effects of Fenbendazole on 5-Fluorouracil-Resistant Colorectal Cancer Cells
Korean research demonstrating fenbendazole retains activity against colorectal cancer cells resistant to 5-FU, a common chemotherapy agent. Suggests potential utility in chemo-resistant cancers and supports the multi-pathway mechanism hypothesis.
→ PubMedThe Joe Tippens Anecdote — Stage 4 SCLC
Joe Tippens, diagnosed with Stage 4 small cell lung cancer and given 3 months to live, claims complete remission after beginning a protocol including fenbendazole, Vitamin E succinate, curcumin, and CBD. His case has not been peer-reviewed and cannot be attributed solely to fenbendazole — but it launched global interest in the compound among cancer patients.
→ Joe Tippens' Site (mycancerstory.rocks)Protocol Support Supplements
Community protocols typically include these alongside fenbendazole — affiliate links support HighPeptides
Frequently Asked Questions
Common questions about fenbendazole and cancer research
Related Research
Explore similar compounds in the HighPeptides database